Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Kirschner

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
The Journal of Clinical Investigation|October 1, 1987
Molecular studies of ceruloplasmin deficiency in Wilson's diseaseM J Czaja, F R Weiner, S J Schwarzenberg, et al.
Der Urologe. Ausg. A|January 13, 2022
[Comparison of catheter-associated quality of life in external urinary diversion: nephrostomy vs. suprapubic catheter]A Wiedemann, M Weinhofer, J Stein, et al.
Der Urologe. Ausg. A|January 10, 2022
[Guidelines for consultations regarding incontinence care products]Andreas Manseck, A Piotrowski, M C Butea, et al.
Leukemia|June 16, 2012
Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemiaS Krentz, J Hof, A Mendioroz, et al.
Der Urologe. Ausg. A|October 4, 2021
[Quality of life for wearers of a suprapubic or transurethral bladder catheter as lifelong permanent care]A Wiedemann, C Gedding, M Heese, et al.
Nature Genetics|August 11, 1998
Positional cloning of the gene for X-linked retinitis pigmentosa 2U Schwahn, S Lenzner, J Dong, et al.
Urologie (Heidelberg, Germany)|March 23, 2022
[Are there benefits for catheter valves for catheter-associated quality of life? : Results of an investigation in 427 catheter wearers with life-long indication]Andreas Wiedemann, A Mourad, C Gedding, et al.
Urologie (Heidelberg, Germany)|May 16, 2024
[Intravesical oxybutynin treatment for neurogenic detrusor overactivity : Efficacy and safety data from clinical practice with the first intravesical oxybutynin treatment authorized in Germany]O Schindler, H Ho, Q Leidl, et al.
Blood Cancer Journal|February 4, 2017
Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemiaP Richter-Pechańska, J B Kunz, J Hof, et al.
Genetic Counseling (Geneva, Switzerland)|April 7, 1999
The Philadelphia story: the 22q11.2 deletion: report on 250 patientsD M McDonald-McGinn, R Kirschner, E Goldmuntz, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
The Journal of Clinical Investigation|October 1, 1987
Molecular studies of ceruloplasmin deficiency in Wilson's diseaseM J Czaja, F R Weiner, S J Schwarzenberg, et al.
Der Urologe. Ausg. A|January 13, 2022
[Comparison of catheter-associated quality of life in external urinary diversion: nephrostomy vs. suprapubic catheter]A Wiedemann, M Weinhofer, J Stein, et al.
Der Urologe. Ausg. A|January 10, 2022
[Guidelines for consultations regarding incontinence care products]Andreas Manseck, A Piotrowski, M C Butea, et al.
Leukemia|June 16, 2012
Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemiaS Krentz, J Hof, A Mendioroz, et al.
Der Urologe. Ausg. A|October 4, 2021
[Quality of life for wearers of a suprapubic or transurethral bladder catheter as lifelong permanent care]A Wiedemann, C Gedding, M Heese, et al.
Nature Genetics|August 11, 1998
Positional cloning of the gene for X-linked retinitis pigmentosa 2U Schwahn, S Lenzner, J Dong, et al.
Urologie (Heidelberg, Germany)|March 23, 2022
[Are there benefits for catheter valves for catheter-associated quality of life? : Results of an investigation in 427 catheter wearers with life-long indication]Andreas Wiedemann, A Mourad, C Gedding, et al.
Urologie (Heidelberg, Germany)|May 16, 2024
[Intravesical oxybutynin treatment for neurogenic detrusor overactivity : Efficacy and safety data from clinical practice with the first intravesical oxybutynin treatment authorized in Germany]O Schindler, H Ho, Q Leidl, et al.
Blood Cancer Journal|February 4, 2017
Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemiaP Richter-Pechańska, J B Kunz, J Hof, et al.
Genetic Counseling (Geneva, Switzerland)|April 7, 1999
The Philadelphia story: the 22q11.2 deletion: report on 250 patientsD M McDonald-McGinn, R Kirschner, E Goldmuntz, et al.
Pageof 9